{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pad:pad-015-statin-therapy",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": ["copilot-agent", "knowledge-graph-agent"],
    "confidence": 0.95,
    "status": "validated",
    "copyright_compliance": "Original content based on general medical knowledge"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pad",
    "type": "pharmacotherapy",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "PAD-015",
    "keywords": ["statin therapy", "PAD", "lipid management", "atorvastatin", "rosuvastatin", "cardiovascular prevention"],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "lower_extremity_arterial_disease",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Statin Therapy in Peripheral Arterial Disease",
    "statement": {
      "text": "High-intensity statin therapy is indicated for all patients with PAD regardless of baseline LDL cholesterol, reducing cardiovascular events, improving limb outcomes, and providing pleiotropic benefits including plaque stabilization and improved endothelial function.",
      "formal": "Target: LDL <70 mg/dL or â‰¥50% reduction; CV event reduction: 25-35%; MALE reduction: 18-30%"
    },
    "explanation": {
      "intuition": "Statins do more than lower cholesterol - they stabilize atherosclerotic plaques, reduce inflammation, and improve blood vessel function. These effects benefit all PAD patients, not just those with elevated lipids.",
      "key_insight": "PAD is an automatic indication for high-intensity statin therapy - no lipid panel needed to start treatment.",
      "technical_details": "HMG-CoA reductase inhibitors (statins) are first-line lipid therapy in PAD. High-intensity regimens (atorvastatin 40-80mg, rosuvastatin 20-40mg) reduce LDL by >50% and provide pleiotropic effects: plaque stabilization, anti-inflammatory action, improved endothelial function, and reduced platelet aggregation. The Heart Protection Study demonstrated 22% reduction in major vascular events with statin therapy. Additional benefits include improved walking distance and reduced major adverse limb events (MALE).",
      "common_misconceptions": [
        "Statins only for high cholesterol - FALSE, indicated for all PAD regardless of LDL",
        "Low-intensity statins are sufficient - FALSE, high-intensity is standard of care",
        "Statins don't help the legs - FALSE, improve walking distance and reduce MALE",
        "Can stop statins after revascularization - FALSE, lifelong therapy required"
      ]
    },
    "pharmacology": {
      "high_intensity_regimens": {
        "atorvastatin": "40-80 mg daily",
        "rosuvastatin": "20-40 mg daily",
        "ldl_reduction": ">50% from baseline"
      },
      "moderate_intensity_regimens": {
        "use": "Only if high-intensity not tolerated",
        "atorvastatin": "10-20 mg daily",
        "simvastatin": "20-40 mg daily",
        "rosuvastatin": "5-10 mg daily"
      },
      "pleiotropic_effects": [
        "Plaque stabilization and reduced rupture risk",
        "Anti-inflammatory (reduced hs-CRP)",
        "Improved endothelial function",
        "Reduced platelet aggregation",
        "Antioxidant properties"
      ]
    },
    "clinical_evidence": {
      "heart_protection_study": {
        "result": "22% reduction in major vascular events with simvastatin",
        "pad_subgroup": "Significant benefit in PAD patients"
      },
      "walking_improvement": {
        "mechanism": "Improved endothelial function and blood flow",
        "magnitude": "Modest improvement in claudication distance"
      },
      "limb_outcomes": {
        "male_reduction": "18-30% reduction in major adverse limb events",
        "graft_patency": "Improved patency after bypass surgery"
      }
    },
    "practical_considerations": {
      "monitoring": {
        "baseline": "Lipid panel, liver enzymes, creatine kinase",
        "follow_up": "Lipid panel at 4-12 weeks, then annually",
        "liver_enzymes": "Only if symptoms develop"
      },
      "adverse_effects": {
        "myalgias": "5-10%, often nocebo effect",
        "myopathy": "Rare, <0.1%",
        "rhabdomyolysis": "Very rare",
        "hepatotoxicity": "Rare, usually reversible"
      },
      "drug_interactions": [
        "CYP3A4 inhibitors increase atorvastatin/simvastatin levels",
        "Gemfibrozil increases myopathy risk",
        "Cyclosporine requires dose adjustment"
      ],
      "intolerance_management": [
        "Try alternative statin",
        "Reduce dose and uptitrate",
        "Alternate day dosing",
        "Consider ezetimibe or PCSK9 inhibitors"
      ]
    },
    "terminology": {
      "snomed_ct": "372912004",
      "icd_10": "Z79.899"
    }
  },
  "skos": {
    "prefLabel": {"@language": "en", "@value": "Statin Therapy in PAD"},
    "altLabel": ["Lipid Management in PAD", "HMG-CoA Reductase Inhibitors in PAD"],
    "definition": {"@language": "en", "@value": "High-intensity statin therapy for cardiovascular and limb protection in peripheral arterial disease patients."},
    "notation": "PAD-015"
  },
  "clinical_features": {
    "presentation": [
      "All PAD patients regardless of symptoms",
      "Pre- and post-revascularization",
      "Claudication and CLTI"
    ],
    "diagnosis": [
      "Baseline lipid panel",
      "Assess for contraindications",
      "Document prior statin use/intolerance"
    ],
    "treatment": [
      "High-intensity statin as first-line",
      "Target LDL <70 mg/dL",
      "Ezetimibe as add-on if needed",
      "PCSK9 inhibitors for refractory cases"
    ]
  },
  "relationships": {
    "prerequisites": ["vascular:pad:pad-013-risk-modification"],
    "enables": ["vascular:pad:cardiovascular-prevention", "vascular:pad:limb-outcomes"],
    "skos:broader": ["vascular:pad:pad-013-risk-modification"],
    "skos:related": ["vascular:pad:antiplatelet-therapy", "vascular:pad:best-medical-therapy"],
    "skos:narrower": []
  },
  "provenance": {
    "sources": [
      {
        "type": "clinical_trial",
        "reference": "Heart Protection Study",
        "evidence_level": "Ia"
      },
      {
        "type": "clinical_guideline",
        "reference": "AHA/ACC Cholesterol Guidelines 2018",
        "evidence_level": "A"
      },
      {
        "type": "clinical_guideline",
        "reference": "ESC/ESVS PAD Guidelines 2024",
        "evidence_level": "A"
      }
    ]
  },
  "pedagogical": {
    "target_audience": ["vascular surgery residents", "internal medicine residents", "medical students"],
    "estimated_time": "15min",
    "learning_objectives": [
      "Identify PAD as an automatic indication for high-intensity statin therapy",
      "Prescribe appropriate statin regimens for PAD patients",
      "Explain the pleiotropic benefits of statins beyond LDL lowering",
      "Manage statin intolerance in PAD patients"
    ],
    "clinical_pearls": [
      "PAD = automatic high-intensity statin indication regardless of LDL",
      "Atorvastatin 80mg or rosuvastatin 40mg is the target",
      "Statins improve walking distance and reduce MALE",
      "True statin myopathy is rare - consider nocebo effect",
      "Never stop statins perioperatively for vascular surgery"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "372912004",
      "codingSystem": "SNOMED-CT",
      "name": "Statin therapy"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "Z79.899",
      "codingSystem": "ICD-10-CM",
      "name": "Long term use of other medication"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "E78.5",
      "codingSystem": "ICD-10-CM",
      "name": "Hyperlipidemia, unspecified"
    }
  ]
}
